Background
==========

Chronic hepatitis C is a major liver related health problem destroying liver architecture leading to cirrhosis and hepatocellular carcinoma. Almost 3% of the world population is infected with this deadly virus and in future, it is predicted that infection will rise to 3 fold of the present number \[[@B1]-[@B6]\]. HCV persist(s) beside the specific humoral responses and the mechanism of viral persistence and viral clearance is not fully understood. During HCV infection, initial fibrosis development is the method to overcome the damage caused by the virus. But the early events are the basis of disease outcome. Initial fibrosis is thought to be reversible, although many studies do not support this phenomenon. As extracellular matrix (ECM) tissues not only involve matrix production but also matrix degradation leading to ECM remodeling \[[@B7]-[@B9]\] Fibrosis is caused by excessive deposition of ECM by histological and molecular reshuffling of various components like collagens, glycoproteins, proteoglycans, matrix proteins and matrix bound growth factors. Fibrosis stage information not only indicates treatment response but also reflect/indicate cirrhosis development disaster \[[@B4],[@B10]-[@B16]\]. ECM metabolism is a balance between ECM deposition and removal influenced by cytokines and growth factors \[[@B17]\]. Genome-wide analysis of abnormal gene expression showed transcripts deregulation differences among normal, mild and severe fibrosis during HCC development with identification of novel serum markers for its early stage. Recent studies suggest that genetic markers may be able to define exact stage of liver fibrosis. For this purpose, limited but functional studies have proposed quite a few genetic markers with individual genes or group of genes \[[@B18],[@B19]\]. Advantage of genetic markers over liver biopsy is intrinsic and long-term while, liver biopsy represents only one time point \[[@B20]\]. Researchers found specific genes such as AZIN1, TLR4, CXCL9, CXCL10, CTGF, ITIH1, SERPINF2, TTR, PDGF, TGF-β1, collagens COL1-A1, TNFα, interleukin, ADAMTS, MMPs, TIMPs, LAMB1, LAMC1, Cadherin, CD44, ICAM1, ITGA, APO and CYP2C8 that showed deregulation during liver fibrosis and may be used to access liver fibrosis and cirrhosis \[[@B11]-[@B28]\]. Microarray is a powerful technique used for the identification of differentially expressed genes within control and experimental samples in different diseases and conditions like cancer development. Very few studies are available that use microarray for the identification of specific genes related to fibrosis \[[@B27],[@B28]\]. In a recent study, Caillot *et al.*used microarray technique and found a significant association of ITIH1, SERPINF2 and TTR gene expression and their related proteins with all fibrosis stages \[[@B28]\]. Expression of these genes and related proteins gradually decreased during the fibrosis development to its end stage cirrhosis. Mostly, HCV expression based studies using microarray are carried out with genotype 1 and 2. Very few studies exploring the role of HCV genotype 3a are done with limited set of genes using real Time PCR. Those do not represent complete picture of HCV and human gene interaction leading to disease progression \[[@B21]-[@B28]\]. In Pakistan, genotype 3a is the major contributor and has strong association with HCC. The aim of the present study was to examine gene expression profiles in the HCV associated liver disease progression. We have identified for the first time, those genes that are differentially regulated in initial fibrosis and advance stage liver cirrhosis 3a patients and identified potential targets that can be used as effective markers to differentiate between fibrotic and cirrhotic liver with genotype 3a. This data may also help to understand the disease stages between initial versus end stage cirrhosis, as there are limited studies concerning HCV genotype 3a disease progression.

Materials and methods
=====================

Patients
--------

This study was conducted at Department of Pathology, Jinnah Hospital, Lahore, Mayo Hospital, Lahore and Liver Centre Faisalabad with collaboration of Applied and Functional Genomics Lab, National Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan. HCV RNA-positive patients were identified among HCV antibody (anti-HCV) positive patients. Patients who had received a previous course of INF or immunosuppressive therapy, or who had clinical evidence of HBV or HIV and any other type of liver cancer were excluded from the study. Patients who refused to have a liver biopsy or for whom it was contraindicated, i.e., because of a low platelet count, prolonged prothrombin time or decompensated cirrhosis were also excluded from the study. The liver biopsy procedure, its advantages and possible adverse effects were explained to the patients. Written informed consent for biopsy procedure was obtained from patients, also contained information about demographic data, possible transmission route of HCV infection, clinical, virological and biochemical data. The study was approved by institutional ethical committee.

Patients and liver biopsy
-------------------------

A group of patient was selected from previously described study with known fibrosis evaluation \[[@B29]\]. Two groups of samples consisted of early fibrosis (F1) and cirrhosis (F4) containing 9 samples each were made. Patient\'s characteristics are given in Table [1](#T1){ref-type="table"}.

###### 

Clinical Characteristics of the patients used in this study

  Factor           Fibrotic patients            Cirrhotic patients         *P*value
  ---------------- ---------------------------- -------------------------- ----------
  Age              37.9 ± 9.5                   48.4 ± 7.1                 \< 0.05
  Sex (M/F)        5/4                          6/3                        0.247
  HAI score        6.05 ± 2.8                   7.6 ± 2.9                  \< 0.05
  Viral load       1.3 ± × 10^7^± 1.5 × 10^7^   2.9 × 10^5^± 2.9 × 10^5^   \< 0.05
  Hb level         12.6 ± 1.2                   12.3 ± 1.2                 0.328
  Bilirubin        0.88 ± 0.2                   1.62 ± 0.31                \< 0.05
  ALT              117.8 ± 55.3                 147.5 ± 61.2               0.091
  ALP              88.1 ± 47.5                  323.8 ± 80.1               \< 0.05
  AST              107.1 ± 66.5                 155.5 ± 90.6               \< 0.05
  Albumin          4.3 ± 0.16                   3.6 ± 0.33                 \< 0.05
  Platelet count   185.1 ± 21.2                 81.6 ± 17.7                \< 0.05

RNA isolation, cDNA and aRNA preparation, and dye labeling for microarray experiments
-------------------------------------------------------------------------------------

RNA from liver biopsy samples were isolated using RNeasy mini elute kit (Qiagen, USA) and preparation of cDNA and aRNA was carried out using RNA ampulse amplification and labeling kit (Kreatech, USA), according to manufacturer. aRNA from HCV infected patients and normal subjects were labeled with Cy3 and Cy5, respectively. A detailed protocol describing each step from start to microarray hybridization can be downloaded from (<http://www.operon.com/products/microarrays/OpArray%20Protocol.pdf>).

Array hybridization and scanning
--------------------------------

Biopsy samples were analyzed on cDNA microarrays (Oparray) containing \> 22000 named genes with 37584 spots. Equal amount of Cy3 and Cy5 (55 pmol each) labeled targets were mixed with 45 μl of OpArray Hyb Buffer. Pre-washing, array hybridization and post-washing of microarray labeled slides were performed according to the manufacturer protocols at 42°C for 18 hours on fully automated workstation \"GeneTAC ™ HybStation\".

Microarray data analysis
------------------------

GeneTAC ™ UC4 × 4 scanner was used for scanning slides at 10 μm resolution for both Cy3 and Cy5 channels. GeneTAC Integrator 4.0 software was initially used for main data output as \"csv\" format file containing all necessary information. This \"csv\" file was converted to \"mev\" format for normalization by using software \"ExpressConverter\" (<http://www.tm4.org/utilities.html>). MIDAS (Microarray Data Analysis System) software was downloaded (<http://www.tm4.org/midas.html>) and used for normalization of data. Fold induction was determined by using formula log~2~Cy5/Cy3. A rank-based permutation method SAM was used to identify significantly expressed genes among fibrosis stages (<http://www-stat.stanford.edu/~tibs/SAM/>). Gene expression patterns through k-means clustering were produced and viewed using freely available programs CLUSTER 3.0 (<http://rana.lbl.gov/EisenSoftware.htm>) and Tree View 1.45 (<http://rana.lbl.gov/downloads/TreeView/>), respectively. To identify biological themes among gene expression profiles, the Expression Analysis Systematic Explorer (EASE) was used (<http://david.abcc.ncifcrf.gov/content.jsp?file=/ease/ease1.htm&type=1>) \[[@B30]\]. The microarray data have been deposited to the GEO accession database (<http://www.ncbi.nlm.nih.gov/geo>) with accession number GSE33258.

Real-time reverse transcriptase (RT)-PCR analysis
-------------------------------------------------

Genes with known function and significantly up-regulated or down-regulated were analyzed by real-time RT-PCR with RNA used for microarray analysis. Total RNA was converted to cDNA using MmLV (Moloney murine leukemia virus). Selected and tested oligonucleotide primer pairs for their specificity were used for real time RT-PCR using ABI 7500 real time PCR system using syber green chemistry. Each experiment was run in triplicate including GAPDH as endogenous control (Table [2](#T2){ref-type="table"}). Each gene was quantified relative to the calibrator. Applied Biosystem Sequence Detection Software and calculations were made by instrument using the equation 2^-ΔΔCT^.

###### 

Primer sequences used for Real time RT-PCR analysis

  Gene name   Primer sequence                      Annealing temp
  ----------- ------------------------------------ ----------------
  OAS         s:5\'-ACTTTAAAAACCCCATTATTGAAA-3\'   58°C
              as:5\'-GGAGAGGGGCAGGGATGAAT-3\'      
  FAM14B      s:5\'-TCTCACCTCATCAGCAGTGACCAG-3\'   60°C
              as:5\'-CCTCTGGAGATGCAGAATTTGG-3\'    
  CASPASE9    s:5\'-ATGTCGTCCAGGGTCTCAAC-3\'       58°C
              as:5\'-GGAAACTGTGAACGGCTCAT-3\'      
  TGFBR       s:5\'-TTCCGTGGGATACTGAGACA-3\'       58°C
              as:5\'-AGATTTCGTTGTGGGTTTCC-3\'      

Results
=======

Patient\'s characteristics
--------------------------

Among 18 patients, equal number of patients belonged to F1 (9) and cirrhotic (9) group. Out of these, six best samples each with good RNA were used for microarray experiments. Normal liver biopsies were also obtained in triplicate. The serum viral load, bilirubin, albumin, and platelet count of cirrhotic patients were significantly low (*P*\< 0.05), while, serum ALP and AST levels were high when compared to patients with F1 stage. There were no significant differences between serum ALT and Hb level in the patients with F1 or cirrhotic stage (Table [1](#T1){ref-type="table"}).

Microarray analysis: expression behavior of significant genes
-------------------------------------------------------------

We found 219 differentially regulated genes in fibrosis versus cirrhotic groups (Figure [1](#F1){ref-type="fig"}). Among these, 107 genes were up-regulated (Figure [2](#F2){ref-type="fig"}) whereas, 112 genes were down-regulated (Figure [3](#F3){ref-type="fig"}). Significant genes with their symbols and functions are listed in Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}. Genes were classified into 31 categories according to their biological functions (Figure [4](#F4){ref-type="fig"}).

![**Significant host genes regulated by HCV infection**. Clustering results for differentially expressed genes between HCV infected patients with initial fibrosis and cirrhosis. Clustering was performed by Cluster 3.0 software. The fold changes in mRNA expression are represented with green and red squares showing down- and up-regulation of genes in liver biopsy samples, respectively. Each vertical column represents an independent experiment, while color scale represents the fold change magnitude.](1479-5876-10-41-1){#F1}

![**Heat map of up-regulated genes**. Clustering results for differentially expressed genes between HCV infected patients with initial fibrosis and cirrhosis. Clustering was performed by Cluster 3.0 software. The fold changes in mRNA expression are represented with green and red squares showing down- and up-regulation of genes in liver biopsy samples, respectively. Each vertical column represents an independent experiment, while color scale represents the fold change magnitude.](1479-5876-10-41-2){#F2}

![**Heat map of down-regulated genes in cirrhotic and non-cirrhotic sample**. Clustering results for differentially expressed genes between HCV infected patients with initial fibrosis and cirrhosis. Clustering was performed by Cluster 3.0 software. The fold changes in mRNA expression are represented with green and red squares showing down- and up-regulation of genes in liver biopsy samples, respectively. Each vertical column represents an independent experiment, while color scale represents the fold change magnitude.](1479-5876-10-41-3){#F3}

###### 

Up-regulated genes in cirrhotic and non-cirrhotic HCV liver biopsy samples

  Function                      Symbol      Description                                                               GeneBank                           *t*- test
  ----------------------------- ----------- ------------------------------------------------------------------------- ---------------------------------- -----------
  Apoptosis                     CASP9       Caspase-9 precursor (EC 3.4.22)                                           [NM_001229.2](NM_001229.2)         0.000207
  apoptosis                     EMP1        Epithelial membrane protein 1                                             [NM_001423.1](NM_001423.1)         1.38E-06
  cell adhesion                 YIF1A       Protein YIF1A                                                             [NM_020470.1](NM_020470.1)         0.000115
  Cell Cycle                    CHES1       Checkpoint suppressor 1                                                   [NM_005197.2](NM_005197.2)         0.047852
  Cell Cycle                    CCNG1       Cyclin-G1                                                                 [NM_004060.3](NM_004060.3)         0.002296
  Cell singling                 LRRC41      Leucine-rich repeat-containing protein 41                                 [NM_006369.4](NM_006369.4)         0.000132
  cell singling                 SCG3        Secretogranin-3 precursor                                                 [NM_013243.2](NM_013243.2)         4.69E-05
  Cell singling                 FLRT1       Leucine-rich repeat transmembrane protein FLRT1 precursor                 [NM_013280.4](NM_013280.4)         0.022495
  cell singling                 SIGLEC8     Sialic acid-binding Ig-like lectin 8 precursor                            [NM_014442.2](NM_014442.2)         0.020819
  cell structure                HYLS1       hydrolethalus syndrome 1                                                  [NM_145014.1](NM_145014.1)         7.28E-05
  cell structure                TOR1AIP1    Torsin-1A-interacting protein 1                                           [NM_015602.2](NM_015602.2)         5.13E-05
  cytokine                      CRLF3       cytokine receptor-like factor 3                                           [XM_001128008.1](XM_001128008.1)   3.25E-06
  cytokine                      PLEKHG6     pleckstrin homology domain containing, family G                           [NM_018173.1](NM_018173.1)         0.004661
  Cytoskeleton                  KRTAP19-5   Keratin-associated protein 19-5                                           [NM_181611.1](NM_181611.1)         0.000296
  cytoskeleton                  COMMD5      COMM domain-containing protein 5                                          [NM_014066.2](NM_014066.2)         8.2E-07
  DNA replication               CENPJ       Centromere protein J                                                      [NM_018451.2](NM_018451.2)         2.22E-05
  DNA replication               TOP3B       DNA topoisomerase 3-beta-1                                                [XM_001129880.1](XM_001129880.1)   1.79E-05
  DNA replication               DDX54       ATP-dependent RNA helicase                                                [NM_024072.3](NM_024072.3)         0.080445
  Energy                        Q5VTU8      ATP synthase,                                                             [NR_002162.1](NR_002162.1)         9.93E-05
  Energy                        COX6A1      Cytochrome c oxidase polypeptide VIa-liver                                [NM_004373.2](NM_004373.2)         0.077561
  Immune response               CRYBB3      Beta crystallin B3                                                        [NM_004076.3](NM_004076.3)         2.89E-05
  Immune response               FCRL3       Fc receptor-like 3 precursor                                              [NM_052939.3](NM_052939.3)         9.14E-06
  Immune response               IFITM2      interferon induced transmembrane protein 2                                [NM_006435.1](NM_006435.1)         0.000197
  Immune response               DEFB114     Beta-defensin 114 precursor                                               [NM_001037499.1](NM_001037499.1)   0.003039
  Immune response               IFNA21      Interferon alpha-21 precursor                                             [NM_002175.1](NM_002175.1)         0.019498
  Immune response               KIR2DL1     Killer cell immunoglobulin-like receptor 3DL2 precursor                   [NM_153443.2](NM_153443.2)         0.014098
  Ion transport                 CANX        Calnexin precursor                                                        [NM_001024649.1](NM_001024649.1)   0.097857
  Ion transport                 CLGN        Calmegin precursor                                                        [NM_004362.1](NM_004362.1)         0.002724
  ion transport                 HHLA3       HERV-H LTR-associating 3 isoform 2                                        [NM_001036645.1](NM_001036645.1)   0.003147
  kinase activity               PDXK        Pyridoxal kinase                                                          [NM_003681.3](NM_003681.3)         0.037672
  kinase activity               PRKCB1      Protein kinase C beta type                                                [NM_002738.5](NM_002738.5)         0.009381
  Lipid Metabolism              PPAPDC3     Probable lipid phosphate phosphatase PPAPDC3                              [NM_032728.2](NM_032728.2)         6.06E-05
  Lipid Metabolism              OSBPL2      Oxysterol-binding protein-related protein 2                               [NM_144498.1](NM_144498.1)         0.016902
  lipid metabolism              Q5R387      Novel protein                                                             [XM_372769.4](XM_372769.4)         0.000376
  liver functions               LEPROT      Leptin receptor precursor                                                 [NM_017526.2](NM_017526.2)         0.107525
  Metabolism                    EMR1        EGF-like module-containing mucin-like hormone receptor-like 1 precursor   [NM_001974.3](NM_001974.3)         0.00022
  Metabolism                    UROD        Uroporphyrinogen decarboxylase                                            [NM_000374.3](NM_000374.3)         0.004853
  metabolism                    DCN         Decorin precursor                                                         [NM_001920.3](NM_001920.3)         0.000807
  Metabolism                    FAHD2B      fumarylacetoacetate hydrolase domain containing 2B                        [XR_016023.1](XR_016023.1)         4.16E-06
  Metabolism                    ACSBG2      Prostatic acid phosphatase precursor                                      [NM_001099.2](NM_001099.2)         1.55E-05
  Metabolism                    ANTXR2      Anthrax toxin receptor 2 precursor                                        [NM_058172.3](NM_058172.3)         1.92E-05
  Metabolism                    CDA         Cytidine deaminase                                                        [NM_001785.2](NM_001785.2)         0.005579
  Metabolism                    CTSD        Cathepsin D precursor                                                     [NM_001909.3](NM_001909.3)         0.028633
  Metabolism                    GOT2        Aspartate aminotransferase, mitochondrial precursor                       [XR_016602.1](XR_016602.1)         0.000258
  Metabolism                    NAT13       Mak3 homolog                                                              [XR_018106.1](XR_018106.1)         5.03E-06
  Metabolism                    TIGD5       Tigger transposable element-derived protein 5                             [NM_032862.2](NM_032862.2)         0.057722
  nervous system                NPAS3       Neuronal PAS domain-containing protein 3                                  [NM_022123.1](NM_022123.1)         0.000115
  nervous system                GPR98       G-protein coupled receptor 98 precursor                                   [NM_032119.3](NM_032119.3)         0.000239
  nervous system                NEUROD2     Neurogenic differentiation factor 2                                       [NM_006160.3](NM_006160.3)         2.17E-05
  nervous system                LAMB2       Laminin subunit beta-2 precursor                                          [NM_002292.3](NM_002292.3)         0.007081
  protein Metabolism            CSDE1       GTPase NRas precursor                                                     [NM_002524.2](NM_002524.2)         0.017096
  protein Metabolism            ENPP7       Ectonucleotide pyrophosphatase                                            [NM_178543.3](NM_178543.3)         0.000321
  protein Metabolism            KIAA1147    KIAA1147 (KIAA1147), mRNA                                                 [NM_001080392.1](NM_001080392.1)   0.000106
  protein Metabolism            KIAA2013    KIAA2013 (KIAA2013), mRNA                                                 [NM_138346.1](NM_138346.1)         2.86E-05
  protein Metabolism            KNG1        Kininogen-1 precursor                                                     [NM_000893.2](NM_000893.2)         0.002086
  protein Metabolism            APOOL       Protein FAM121A precursor                                                 [NM_198450.3](NM_198450.3)         0.019311
  Protein modulation            HAT1        Histone acetyltransferase type B catalytic subunit                        [NM_001033085.1](NM_001033085.1)   0.000447
  Protein modulation            RIMS2       Regulating synaptic membrane exocytosis protein 2                         [NM_014677.2](NM_014677.2)         0.000572
  Protein modulation            UBL4B       Ubiquitin-like protein 4B                                                 [NM_203412.1](NM_203412.1)         2.33E-05
  Protein modulation            UBE1L       Ubiquitin-activating enzyme E1 homolog                                    [NM_003335.2](NM_003335.2)         0.021531
  Protein modulation            USP54       ubiquitin specific protease 54                                            [NM_152586.2](NM_152586.2)         0.005541
  Protein synthesis             RNPEP       Aminopeptidase B                                                          [NM_020216.3](NM_020216.3)         0.0218
  PTMs                          SNF1LK2     Serine/threonine-protein kinase SNF1-like kinase 2                        [NM_015191.1](NM_015191.1)         0.00037
  RNA modelling and synthesis   IMP3        U3 small nucleolar ribonucleoprotein protein IMP3                         [NM_018285.2](NM_018285.2)         7.13E-05
  RNA modelling and synthesis   SF3A2       Splicing factor 3A subunit 2                                              [NM_007165.4](NM_007165.4)         0.123287
  Signal Transduction           CACNB3      Voltage-dependent L-type calcium channel subunit beta-3                   [NM_000725.2](NM_000725.2)         0.00248
  Signal Transduction           PCSK5       Proprotein convertase subtilisin/kexin type 5 precursor                   [NM_006200.2](NM_006200.2)         6.62E-06
  Signal Transduction           VDAC3       Voltage-dependent anion-selective channel protein 3                       [XR_019103.1](XR_019103.1)         0.000231
  Signal Transduction           ITGB6       Integrin beta-6 precursor                                                 [NM_000888.3](NM_000888.3)         0.008005
  sulphur metabolism            FAM119B     family with sequence similarity 119                                       [NM_015433.2](NM_015433.2)         0.018357
  Transcriptional regulation    LYSMD3      LysM and putative peptidoglycan-binding domain-containing protein 3       [NM_198273.1](NM_198273.1)         0.004237
  transcriptional regulation    FOXI1       Forkhead box protein I1                                                   [NM_012188.3](NM_012188.3)         1.84E-05
  transcriptional regulation    MYCL1       L-myc-1 proto-oncogene protein                                            [NM_001033081.1](NM_001033081.1)   4.97E-05
  transcriptional regulation    MYOD1       Myoblast determination protein 1                                          [NM_002478.4](NM_002478.4)         7.25E-06
  transcriptional regulation    PRDM5       PR domain zinc finger protein 5                                           [NM_018699.2](NM_018699.2)         1.03E-07
  Transcriptional regulation    YBX1        Nuclease sensitive element-binding protein 1                              [XM_001129294.1](XM_001129294.1)   6.12E-05
  Transcriptional regulation    ANKHD1      Eukaryotic translation initiation factor 4E-binding protein 3             [NM_020690.4](NM_020690.4)         0.041134
  transcriptional regulation    RUNX2       Runt-related transcription factor 2                                       [NM_001024630.2](NM_001024630.2)   0.064668
  Transcriptional regulation    SUSD4       Sushi domain-containing protein 4 precursor                               [NM_017982.2](NM_017982.2)         0.004775
  Transport                     CLPB        Caseinolytic peptidase B protein homolog                                  [NM_030813.3](NM_030813.3)         0.027308
  Transport                     K1024       UPF0258 protein KIAA1024                                                  [NM_015206.1](NM_015206.1)         0.001564
  transport                     NOS2A       nitric oxide synthase 2, inducible1                                       [NM_000625](NM_000625)             0.017057
  transport                     SCGN        Secretagogin                                                              [NM_006998.3](NM_006998.3)         2E-06
  Transport                     FBXO32      F-box only protein 32                                                     [NM_148177.1](NM_148177.1)         0.043284
  Uncharacterized               C12orf41    CDNA FLJ12670                                                             [NM_017822.2](NM_017822.2)         0.001604
  Uncharacterized               C17orf56    CDNA FLJ31528                                                             [NM_144679.1](NM_144679.1)         1.11E-06
  Uncharacterized               C21orf59    Uncharacterized protein                                                   [NM_021254.1](NM_021254.1)         0.001335
  Uncharacterized               C4orf20     CDNA FLJ11200                                                             [NM_018359.1](NM_018359.1)         0.000365
  Uncharacterized               C9orf7      Uncharacterized protein                                                   [NM_017586.1](NM_017586.1)         0.002015
  Uncharacterized               C9orf91     C9orf91 protein                                                           [NM_153045.2](NM_153045.2)         2.21E-06
  Uncharacterized               KIAA0562    glycine-, glutamate-, thienylcyclohexylpiperidine-binding protein         [NM_014704.2](NM_014704.2)         5.09E-05
  Uncharacterized               KLHL30      kelch-like 30                                                             [NM_198582.1](NM_198582.1)         5.06E-06
  Uncharacterized               LOC728660   \-                                                                        [XM_001128340.1](XM_001128340.1)   0.000153
  Uncharacterized               Q71MF4      \-                                                                        \-                                 7.89E-05
  Uncharacterized               Q8TCQ8      CDNA FLJ90801 fis, clone Y79AA1000207                                     [XM_001134000.1](XM_001134000.1)   0.028312
  Uncharacterized               Q8WY63      PP565                                                                     \-                                 0.017959
  Uncharacterized               ST8SIA6     Alpha-2,8-sialyltransferase 8F                                            [NM_001004470.1](NM_001004470.1)   0.008458
  Uncharacterized               C10orf6     Uncharacterized protein C10orf6                                           [NM_018121.2](NM_018121.2)         0.000673
  Uncharacterized               O75264      \-                                                                        [XM_209196.5](XM_209196.5)         0.01282
  Uncharacterized               Q9NW32      CDNA FLJ10346                                                             \-                                 0.038301
  Uncharacterized               S11Y        Putative S100 calcium-binding protein                                     [XM_001126350.1](XM_001126350.1)   0.002549
  Vision                        ST13        Hsc70-interacting protein                                                 [XR_018201.1](XR_018201.1)         0.012047
  Vision                        DUPD1       dual specificity phosphatase and pro isomerase domain containing 1        [NM_001003892.1](NM_001003892.1)   4.5E-06
  Vision                        OR6P1       Olfactory receptor 6P1                                                    \-                                 1.78E-05
  Vision                        ARSH        arylsulfatase H                                                           [NM_001011719.1](NM_001011719.1)   0.002229
  Vision                        OR51F2      Olfactory receptor 51F2                                                   [NM_001004753.1](NM_001004753.1)   0.018938
  Vision                        OR7G3       Olfactory receptor 7G3                                                    [NM_001001958.1](NM_001001958.1)   0.077667

###### 

Down-regulated genes in cirrhotic and non-cirrhotic HCV liver biopsy samples

  Function                      Symbol      Description                                                     GeneBank                           *t*- test
  ----------------------------- ----------- --------------------------------------------------------------- ---------------------------------- -----------
  Apoptosis                     BCL2L12     Bcl-2-related proline-rich protein                              [NM_001040668.1](NM_001040668.1)   0.000335
  Apoptosis                     PDCD1       Programmed cell death protein 1 precursor                       [NM_005018.1](NM_005018.1)         7.94E-06
  carbohydrate metabolism       OGDHL       oxoglutarate dehydrogenase-like                                 [NM_018245.1](NM_018245.1)         0.000909
  cell adhesion                 THUMPD1     THUMP domain-containing protein 1                               [NM_017736.3](NM_017736.3)         0.044141
  Cell Cycle                    AKAP4       A-kinase anchor protein 11                                      [NM_016248.2](NM_016248.2)         0.000598
  cell cycle                    TINF2       TERF1-interacting nuclear factor 2                              [NM_012461](NM_012461)             0.045359
  cell cycle                    VEGFB       vascular endothelial growth factor B                            [NM_003377](NM_003377)             0.017886
  cell singling                 GRIN3A      Glutamate \[NMDA\] receptor subunit 3A precursor                [NM_133445.1](NM_133445.1)         1.17E-06
  cell singling                 Q8N9G6      similar to nuclear pore membrane protein 121                    [XM_498333.2](XM_498333.2)         7.46E-05
  Cell Structure                ENO3        Beta-enolase                                                    [NM_001976.2](NM_001976.2)         0.050309
  cell structure                MAP6D1      MAP6 domain-containing protein 1                                [NM_024871.1](NM_024871.1)         0.034981
  cytokine                      IL13RA2     Interleukin-13 receptor alpha-2 chain precursor                 [NM_000640.2](NM_000640.2)         0.024814
  Cytoskeleton                  LLGL1       Lethal(2) giant larvae protein homolog 1                        [NM_004140.3](NM_004140.3)         0.008177
  cytoskeleton                  SNX17       Sorting nexin-17                                                [NM_014748.2](NM_014748.2)         5.41E-05
  DNA binding proteins          ZNF236      Zinc finger protein 236                                         [NM_007345.2](NM_007345.2)         1.54E-07
  DNA binding proteins          ZBED4       Zinc finger BED domain-containing protein 4                     [NM_014838.1](NM_014838.1)         0.003728
  DNA replication               WRB         Tryptophan-rich protein                                         [NM_004627.2](NM_004627.2)         0.000578
  Energy                        ABHD2       ATP-binding cassette sub-family F member 2                      [NM_005692.3](NM_005692.3)         0.000193
  Energy                        ATAD2       ATPase family AAA domain-containing protein 2                   [NM_014109.2](NM_014109.2)         8.59E-06
  Energy                        PSMD11      26S proteasome non-ATPase regulatory subunit 11                 [NM_002815.2](NM_002815.2)         0.000415
  Energy                        PSMD4       26S proteasome non-ATPase regulatory subunit 4                  [NM_002810.2](NM_002810.2)         0.003878
  Energy                        SYDE1       synapse defective 1                                             [NM_033025.4](NM_033025.4)         0.000222
  Immune response               ATG16L2     ATG16 autophagy related 16-like 2                               [NM_033388.1](NM_033388.1)         1.31E-05
  Immune response               IL8RB       High affinity interleukin-8 receptor B                          [NM_001557.2](NM_001557.2)         0.00539
  immune response               PTGS2       prostaglandin-endoperoxide synthase 2                           [NM_000963](NM_000963)             0.00504
  immune response               FAM14B      Interferon alpha-inducible protein 27-like protein 1            [NM_145249](NM_145249)             0.006008
  immune response               OAS2        2\'-5\'-oligoadenylate synthase 2                               [NM_016817](NM_016817)             0.009299
  Ion transport                 DSG4        Desmoglein-4 precursor                                          [NM_177986.2](NM_177986.2)         1.23E-05
  Ion transport                 SLC10A5     Sodium/bile acid cotransporter 5 precursor                      [NM_001010893.2](NM_001010893.2)   6.5E-08
  Ion transport                 CAPN7       Calpain-7                                                       [NM_014296.2](NM_014296.2)         0.003785
  ion transport                 MT1E        Metallothionein-1E                                              [NM_175617.3](NM_175617.3)         0.001767
  Lipid Metabolism              DEGS2       sphingolipid C4-hydroxylase/delta 4-desaturase                  [NM_206918.1](NM_206918.1)         0.008105
  lipid metabolism              CHKA        Choline kinase alpha                                            [NM_001277.2](NM_001277.2)         0.003609
  lipid metabolism              ADA         bubblegum related protein                                       [NM_030924.3](NM_030924.3)         6.6E-05
  Metabolism                    HMGCL       Hydroxymethylglutaryl-CoA lyase, mitochondrial precursor        [NM_000191.2](NM_000191.2)         0.010122
  metabolism                    HMGCS1      Hydroxymethylglutaryl-CoA synthase, cytoplasmic                 [NM_002130.4](NM_002130.4)         1.2E-05
  Metabolism                    SH3BGRL3    SH3 domain-binding glutamic acid-rich-like protein 3            [NM_031286.3](NM_031286.3)         0.000157
  Metabolism                    ARHGAP5     Rho GTPase-activating protein 5                                 [NM_001173.2](NM_001173.2)         0.010513
  Metabolism                    CKM         Creatine kinase M-type                                          [NM_001824.2](NM_001824.2)         0.000689
  Metabolism                    CPT1A       Carnitine O-palmitoyltransferase I, liver isoform               [NM_001031847.1](NM_001031847.1)   0.008256
  Metabolism                    USP53       Inactive ubiquitin carboxyl-terminal hydrolase 53               [NM_019050.1](NM_019050.1)         2.46E-06
  morphogenesis                 SLC33A1     Acetyl-coenzyme A transporter 1                                 [NM_004733.2](NM_004733.2)         8.12E-06
  morphogenesis                 PDYN        Beta-neoendorphin-dynorphin precursor                           [NM_024411.2](NM_024411.2)         0.055803
  nervous system                NINJ2       Ninjurin-2 (Nerve injury-induced protein 2)                     [NM_016533.4](NM_016533.4)         0.004163
  protein Metabolism            GON4L       GON-4-like protein                                              [NM_001037533.1](NM_001037533.1)   0.00137
  protein Metabolism            PHACTR4     phosphatase and actin regulator 4 isoform 1                     [NM_001048183.1](NM_001048183.1)   0.000139
  protein Metabolism            OTUD7A      OTU domain-containing protein 7A                                [XM_001127986.1](XM_001127986.1)   0.00394
  protein Metabolism            Q96NT9      GR AF-1 specific protein phosphatase                            [XM_497354.1](XM_497354.1)         7.5E-05
  protein Metabolism            WFDC13      Protein WFDC13 precursor                                        [NM_172005.1](NM_172005.1)         0.080737
  Protein modulation            SMAP1       Stromal membrane-associated protein 1                           [NM_001044305.1](NM_001044305.1)   8.97E-08
  Protein modulation            DYRK1B      Dual specificity tyrosine-phosphorylation-regulated kinase 1B   [NM_004714.1](NM_004714.1)         0.001009
  Protein modulation            COQ5        Ubiquinone biosynthesis methyltransferase COQ5                  [NM_032314.3](NM_032314.3)         2.07E-05
  Protein modulation            MTIF2       Translation initiation factor IF-2                              [NM_001005369.1](NM_001005369.1)   0.002917
  Protein synthesis             MRPL46      39S ribosomal protein L46, mitochondrial precursor              [NM_022163.2](NM_022163.2)         2.83E-06
  Protein synthesis             MRPS35      28S ribosomal protein S35, mitochondrial precursor              [NM_021821.2](NM_021821.2)         0.000245
  protein synthesis             PLAT        Tissue-type plasminogen activator precursor                     [NM_000930.2](NM_000930.2)         0.014382
  protein synthesis             SENP1       Sentrin-specific protease 1                                     [NM_014554.2](NM_014554.2)         1.63E-06
  protein synthesis             ELL         RNA polymerase II elongation factor ELL                         [NM_006532.2](NM_006532.2)         0.003242
  Protein synthesis             PACS1       Phosphofurin acidic cluster sorting protein 1                   [NM_018026.2](NM_018026.2)         0.005118
  protein synthesis             PTP4A1      Protein tyrosine phosphatase type IVA protein 1                 [NM_003463.3](NM_003463.3)         0.001949
  PTMs                          SNF1LK      Serine/threonine-protein kinase SNF1-like kinase 1              [NM_173354.3](NM_173354.3)         0.000169
  Reproduction                  LOC283116   similar to Tripartite motif protein 49                          [XR_016154.1](XR_016154.1)         5.32E-07
  Reproduction                  Q5VYG3      OTTHUMP00000018545                                              \-                                 2.51E-05
  RNA modelling and synthesis   EXOSC2      Exosome complex exonuclease RRP4                                [NM_014285.4](NM_014285.4)         0.080373
  RNA modelling and synthesis   RBM41       RNA-binding protein 41                                          [NM_018301.2](NM_018301.2)         0.002623
  RNA modelling and synthesis   ADCY2       Double-stranded RNA-specific adenosine deaminase                [NM_001111.3](NM_001111.3)         6.64E-05
  Signal Transduction           FGF17       Fibroblast growth factor 17 precursor                           [NM_003867.2](NM_003867.2)         0.000254
  Signal Transduction           ADH1A       Adenylate cyclase type 2                                        [NM_020546.2](NM_020546.2)         0.00139
  Signal Transduction           HOMER1      Homer protein homolog 1                                         [NM_004272.3](NM_004272.3)         0.011954
  Signal Transduction           TMEM100     Transmembrane protein 100                                       [NM_018286.1](NM_018286.1)         3.31E-05
  sulphur metabolism            FAM62B      family with sequence similarity 62                              [NM_020728.1](NM_020728.1)         1.6E-05
  transcriptional regulation    CRAMP1L     Protein cramped-like                                            [NM_020825.2](NM_020825.2)         0.006587
  transcriptional regulation    FOXK2       Forkhead box protein K2                                         [XM_001134364.1](XM_001134364.1)   0.00156
  transcriptional regulation    HMGN2       Nonhistone chromosomal protein HMG-17                           [XM_001133530.1](XM_001133530.1)   0.01162
  Transcriptional regulation    NANOGP8     Homeobox protein NANOGP8                                        \-                                 0.000264
  transcriptional regulation    NFXL1       nuclear transcription factor                                    [NM_152995.4](NM_152995.4)         8.53E-05
  transcriptional regulation    NR1I3       Orphan nuclear receptor NR1I3                                   [NM_001077470.1](NM_001077470.1)   0.00247
  Transcriptional regulation    SNORA32     Protein JOSD3                                                   [NR_003032.1](NR_003032.1)         0.107321
  Transcriptional regulation    GTF2B       Transcription initiation factor IIB                             [NM_001514.3](NM_001514.3)         0.002357
  Transcriptional regulation    PAX8        Paired box protein Pax-8                                        [NM_003466.3](NM_003466.3)         4.89E-05
  Transcriptional regulation    CTCFL       Transcriptional repressor CTCFL                                 [NM_080618.2](NM_080618.2)         0.003129
  Transcriptional regulation    EEF1AL3     Eukaryotic translation elongation factor 1 alpha 1              \-                                 0.000917
  Transcriptional regulation    INTU        PDZ domain-containing protein 6                                 [NM_015693.2](NM_015693.2)         0.003842
  transcriptional regulation    TGFBR2      TGF-beta receptor type-2 precursor                              [NM_001024847.1](NM_001024847.1)   0.007651
  Transport                     KIF1A       Kinesin-like protein KIF1A                                      [NM_004321.4](NM_004321.4)         0.002119
  transport                     NUP160      Nuclear pore complex protein Nup160                             [NM_015231.1](NM_015231.1)         3.11E-06
  transport                     SLIT3       Slit homolog 3 protein precursor                                [NM_003062.1](NM_003062.1)         0.000577
  Transport                     AMICA1      Junctional adhesion molecule-like precursor                     [NM_153206.1](NM_153206.1)         3.86E-06
  Transport                     KIF17       Kinesin-like protein KIF17                                      [NM_020816.1](NM_020816.1)         0.007279
  Transport                     SCAMP4      secretory carrier membrane protein 4                            [NM_079834.2](NM_079834.2)         0.026864
  transport                     MUC6        Mucin-6 precursor (Gastric mucin-6)                             [XM_290540.7](XM_290540.7)         0.054436
  Transport                     SNF8        Vacuolar sorting protein SNF8                                   [XR_019363.1](XR_019363.1)         0.000425
  Uncharacterized               C14orf101   Uncharacterized protein C14orf101                               [NM_017799.3](NM_017799.3)         0.02931
  Uncharacterized               C16orf57    C16orf57 protein                                                [NM_024598.2](NM_024598.2)         0.000456
  Uncharacterized               Q6PDB4      \-                                                              \-                                 2.68E-05
  Uncharacterized               Q6ZMS0      CDNA FLJ16729                                                   \-                                 0.027141
  Uncharacterized               Q6ZRH2      CDNA FLJ46361                                                   \-                                 1.15E-06
  Uncharacterized               Q8NB05      CDNA FLJ34424                                                   \-                                 0.000459
  Uncharacterized               SEC14L5     \-                                                              [XM_032693.5](XM_032693.5)         2.77E-06
  Uncharacterized               CD164L2     CD164 sialomucin-like 2 protein precursor                       [NM_207397.2](NM_207397.2)         0.000576
  Uncharacterized               CNOT6       CCR4-NOT transcription complex subunit                          [NM_015455.3](NM_015455.3)         0.000838
  Uncharacterized               Q6YL35      \-                                                              \-                                 0.00218
  Uncharacterized               Q8N2T9      CDNA: FLJ21438                                                  [XM_029084.8](XM_029084.8)         0.007508
  Uncharacterized               Q96NM1      CDNA FLJ30594                                                   \-                                 0.000447
  Uncharacterized               C22orf30    Novel protein (DJ694E4.2 protein)                               [NM_173566.1](NM_173566.1)         0.000611
  Uncharacterized               SBDS        Shwachman-Bodian-Diamond syndrome                               [NM_016038.2](NM_016038.2)         0.006543
  Vision                        ARSJ        arylsulfatase family, member J                                  [NM_024590.3](NM_024590.3)         0.000249
  vision                        OR51T1      Olfactory receptor 51T1                                         [NM_001004759.1](NM_001004759.1)   0.000408
  vision                        OR6C1       Olfactory receptor 6C1                                          [NM_001005182.1](NM_001005182.1)   0.000136
  vision                        DUSP5       Dual specificity protein phosphatase 5                          [NM_004419.3](NM_004419.3)         0.000125
  vision                        OR5K1       Olfactory receptor 5K1 (HTPCRX10)                               [NM_001004736.2](NM_001004736.2)   0.000169
  Vision                        RPGR        retinitis pigmentosa GTPase regulator                           [NM_001023582.1](NM_001023582.1)   0.007569

![**Distribution of genes according to their functions**. Genes were grouped in 31 different categories.](1479-5876-10-41-4){#F4}

Significantly synchronized genes with known biological functions
----------------------------------------------------------------

The differentially regulated genes were grouped according to their biological functions by EASE program that uses information from Entrez Gene (<http://jura.wi.mit.edu/entrez_gene/>) and KEGG database (<http://www.genome.jp/kegg/kegg1.html>). Our results showed variation in gene regulation in both early fibrosis and cirrhosis stages (Figure [1](#F1){ref-type="fig"}). Out of 107 up-regulated gens, 65 belonged to early fibrosis stage, whereas, 42 genes belonged to the cirrhotic stage. Genes related to immune response, cell signaling, kinase activity, lipid metabolism, metabolism, vision and transcriptional regulation were up-regulated in both early fibrosis and cirrhotic samples (Table [2](#T2){ref-type="table"}). We found that most genes related to apoptosis, cell structure, cytoskeleton, nervous system protein metabolism, protein modulation, signal transduction, transcriptional regulation and transport were up-regulated in early fibrosis. Many uncharacterized genes were also found up-regulated in liver disease progression. We identified 112 genes (F1 = 92; F4 = 20) related to above mentioned pathways down-regulated when fibrosis lead to cirrhotic stage (Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}). Genes related to these pathways showed varied response and none of biological function was specifically related to any liver disease stage (Table [4](#T4){ref-type="table"} and Figure [3](#F3){ref-type="fig"}).

Independent validation of candidate genes using quantitative real-time RT-PCR
-----------------------------------------------------------------------------

Total RNA extracted from infected liver biopsies was used for real time RT-PCR analysis to validate microarray data. Expression analysis of the genes involved in apoptosis, immune response and transcriptional regulation was performed. We randomly selected four genes, CASPASE9, FAM14B, OAS2 and TGFBR2 from our study. CASPASE9 is apoptosis related gene, FAM14B and OAS2 are immune responsive genes, whereas, TGFBR2 is multifunctional gene and found to be up-regulated in fibrosis.

Discussion
==========

Liver fibrosis can progress to cirrhosis after an interval of 15-20 years in patients with HCV \[[@B31]\]. It is very important to identify such markers that can differentiate liver fibrosis from cirrhosis. Liver biopsy is a common tool for the detection of liver current situation but due to some limitations its use as diagnostic tool is denied. Microarray analysis is an emerging and novel approach to study gene expression in HCV associated fibrosis and cirrhosis. As liver gene expression in HCV patients is variable and it might be partially dependent on the corresponding genotype \[[@B32]\]. In this study, we specially focused on gene expression analysis in patients with genotype 3a that is most common in our region. We found that many genes associated with apoptosis, several cellular functions, immune response, metabolism including energy, liver, sulphur; protein metabolism, transcriptional regulation, signal transduction, transport, DNA replication were dys-regulated both in early fibrosis and cirrhosis. In some cases, gene expression tends to be increased from initial fibrosis to cirrhosis. Induction of gene expression associated with proapoptotic, proinflammatory and proliferative activities is in accordance with previous studies \[[@B18],[@B27],[@B33]-[@B35]\]. Although, we found some dysregulation of genes related to vision and nervous system first time.

Differential expression of apoptosis related genes in HCV associated initial fibrosis and cirrhosis
---------------------------------------------------------------------------------------------------

In this study, host genes involved in apoptosis (Figure [5](#F5){ref-type="fig"}) such as BCL212 and PDCD1 showed down-regulation in initial fibrosis and significant up-regulation in cirrhosis, whereas, expression levels for CASP9 and EMP1 genes were high at initial stage and were down-regulated in cirrhosis stage. Regulation of apoptotic inducer and program cell death genes, BCL212 and PDCD1 in cirrhosis is according to previous observations where pro-apoptotic gene signaling has been observed in infection with HCV \[[@B36],[@B37]\]. CASP9 is known as apoptosis initiator \[[@B38]\] and EMP1 is also found to induce apoptosis \[[@B39],[@B40]\]. Expression of caspases is higher in early and moderate HCV infection, and enhanced apoptosis occur through the intrinsic apoptotic pathway via mitochondria \[[@B41],[@B42]\].

![**Differential expression of apoptotic genes in HCV associated initial fibrosis and cirrhosis.**Clustering results for differentially expressed genes between HCV infected patients with initial fibrosis and cirrhosis according to their functions. Clustering was performed by Cluster 3.0 software. Genes shown in red are up-regulated, while down-regulated genes are shown in green. Genes shown in black have no expression changes. Gene expression profiles were presented on a 2-fold change scale.](1479-5876-10-41-5){#F5}

Cellular functions, cell cycle, signaling and cytoskeleton associated genes
---------------------------------------------------------------------------

Genes related to various cellular functions showed different expression patterns (Figure [6](#F6){ref-type="fig"}). The cytoskeleton (COMMD5, KRTAP19-5, LLGL1 and SNX17) related genes were down-regulated in cirrhosis (F4). Most cell structure related genes were up-regulated in initial fibrosis (HYLS1, MAP6D1 and TOR1AIP1) and genes related to cell adhesion, cell cycle and signaling showed differential expression in both initial fibrosis and cirrhosis. It has been observed that HCV RNA synthesis may require an intact cytoskeleton \[[@B43]\]; our data indicated that many genes related to cytoskeleton were regulated by HCV infection.

![**Parallel expression of genes associated with Cellular functions, cell cycle, signaling and cytoskeleton in F1 versus F4.**Genes shown in red are up-regulated, while down-regulated genes are shown in green. Genes shown in black have no expression changes. Gene expression profiles were presented on a 2-fold change scale.](1479-5876-10-41-6){#F6}

Genes associated with Immune response and cytokines
---------------------------------------------------

A number of genes related to immune response and cytokines were identified (Figure [7](#F7){ref-type="fig"}). ATG16L2, DEFB114, FAM14B, IFNA21, IL8RB and KIR2DL genes were up-regulated in cirrhosis, whereas, FCRL3, IFITM2 and OAS2 genes were up-regulated in initial fibrosis. Genes related to cytokine regulation, IL13RA2, PLEKHG6 and XCL2 were down-regulated in initial fibrosis except CRLF3 gene. Interleukin related gene expression has been found to be increased at pathology stage 3 and 4 and which is concurrent with the present study and is associated with metastatsis, cell proliferation or angiogenesis \[[@B37],[@B44]\]. An increased expression of immune responsive genes and cytokines as fibrosis progress is in agreement with previous evidence that liver inflammation may enhance with increase in infected hepatocytes \[[@B45]\]. FCRL3, a genetically conserved gene family encodes orphan cell surface receptors bearing high structural homology to classical Fc receptors, with multiple extracellular Ig domains and either ITAMs, ITIMs, or both in the intracellular domains. The natural ligands of these family members are still unknown but due to their signaling domains and expression on multiple immune cell types, these members likely modulate immune cell functions by affecting signaling pathways \[[@B46]\]. FCRL3 is expressed predominantly in B lymphocytes in lymph nodes and germinal centers \[[@B47]-[@B49]\].

![**Expression profiles of immune responsive and cytokines associated genes.**Clustering results for differentially expressed genes between HCV infected patients with initial fibrosis and cirrhosis according to their functions. Clustering was performed by Cluster 3.0 software. Gene expression profiles were presented on a 2-fold change scale.](1479-5876-10-41-7){#F7}

Previous studies revealed that IFITM2 and IFITM3 (two structurally related cell plasma membrane proteins) interrupt early steps entry and/or uncoating of the viral infection. Interferon-induced transmembrane (*IFITM*) genes are transcribed in most tissues with the exception of *IFITM5*interferon inducible gene. IFITM genes are involved in early development, cell adhesion, and control of cell growth. Elevated gene expression triggered by past or chronic inflammation can prevent spreading of pathogens by limiting host cell proliferation. Low level of expression is sufficient to capture the growth of cells, whereas, the loss of expression causes tumor growth. This gene is termed as tumor suppressor. However, in many cancers it is observed that despite high level of IFITM, it represents tumor progression stage especially where the one of anti-proliferative interferon pathway is shut down. The role of ATG protein in membrane trafficking is mostly not clear. ATGL16 is thought to play role in autophagosome formation in association with RAB33B. It is also considered an active player in HCV replication and assembly \[[@B50],[@B51]\].

Natural killer cells are the important player of innate immune response. KIRDL gene expression is found to be high in chronic HCV patients \[[@B52]\]. We found the KIR2DL1 gene expression high in patients with cirrhosis as compared to initial fibrosis stage. OAS synthesized in response to IFN-alpha stimulation. In infected cells, OAS enzymatic activity is induced by double-stranded RNAs, such as the intermediates of replication of RNA viruses or folded single stranded RNAs. OAS catalyzes polymerization of adenosine triphosphate into oligoadenylate that, in turn, activates a cellular endoribonuclease, RNase L, at subnanomolar concentrations. RNase L degrades cellular and viral single-stranded RNAs. Thus, viral replication is inhibited as a result of protein synthesis inhibition in a totally non-virus specific way \[[@B53]\]. We found high expression of OAS2 gene in fibrotic samples as compared to the last stage cirrohsis. This may be a way to stop viral replication but as the disease steps forward, virus overcome the host immune response to replicate itself.

Genes associated with different metabolic processes
---------------------------------------------------

A number of genes associated with different metabolism (processes/pathways) like energy, kinases, lipid and sulphur metabolism were identified among significantly expressed arrays (Figure [8](#F8){ref-type="fig"}). Several studies observed that HCV induces alterations in lipid metabolism that can lead to oxidative stress \[[@B54],[@B55]\]. Consistent with these observations, we found six genes, ADA, CHKA, DEGS2, OSBPL2, PPAPDC3, and Q5R387; which are involved in lipid biosynthesis, tumor cell growth by phosphatidyl-ethanolamine biosynthesis, negative regulation of myoblast differentiation and hydrolyzation of phospholipids into fatty acids etc. This finding is in agreement with Diamond *et al*.; that host cell lipid metabolism may represent an area for future HCV antiviral therapies \[[@B56]\]. We found two genes FAM119B and FAM62B associated with sulphur metabolism which were up-regulated in cirrhotic samples. A number of genes related to energy mechanism such as PSMD4, PSMD11, ABHD2, ATAD2 and COX6A1 were up-regulated while, SYDE1 and Q5VTUB genes were down-regulated in cirrhotic samples. Two genes PDXK and PRKCB1 with kinase activity, and one gene, OGDHL linked to carbohydrate metabolism were also identified. Role of PRKCB1 (also known as PKC) in cell growth and differentiation control is known. It has been also found elevated in breast and pituitary tumors and malignant gliomas \[[@B57]-[@B59]\]. PKC was also found up regulated in hepatocellular carcinoma which can lead to hyper proliferation of the HCV infected tissues \[[@B60]\].

![**Genes associated with different metabolic processes**. Clustering was performed by Cluster 3.0 software. Genes shown in red are up-regulated, while down-regulated genes are shown in green. Genes shown in black have no expression changes. Gene expression profiles were presented on a 2-fold change scale.](1479-5876-10-41-8){#F8}

Genes associated with protein synthesis, modulation and metabolism
------------------------------------------------------------------

Many genes involved in protein synthesis, modulation and metabolism have increased or decreased expression in patients with HCV (Figure [9](#F9){ref-type="fig"}). Genes representing protein synthesis were down-regulated in initial fibrosis and showed significant increased expression in cirrhotic samples. Two genes associated with protein post-translational modifications (PTMs) were also identified that showed increased expression in cirrhosis. Some genes linked with protein metabolism like GON4L, OTUD7A, PHACTR4, Q96NT9 and WFDC13 showed low expression in initial fibrosis, while CSDE1, ENPP7, KIAA1147, KIAA2013 and KNG1 were up-regulated in early fibrosis. It was interesting to know that previous studies have not shown the regulation of PTMs and protein synthesis with respect to HCV, although other viruses such as HIV have shown these trends. However, our findings were in agreement with Blackham et al. who showed these types of regulations in HCV infected hepatocytes \[[@B61]\].

![**Genes associated with protein synthesis, modulation and metabolism**. Genes shown in red are up-regulated, while down-regulated genes are shown in green. Genes shown in black have no expression changes.](1479-5876-10-41-9){#F9}

Transcriptional regulation and signal transduction related genes
----------------------------------------------------------------

Several genes associated with transcriptional regulation and signal transductions were identified (Figure [10](#F10){ref-type="fig"}). Most genes were down-regulated both in HCV initial fibrosis and cirrhosis. However, ANKHD1, CRAMP1L, FOXK2, GTF2B, HMGN2, NR1I3, PAX8, RUNX2 and SUSD4 genes showed increased trend in cirrhotic samples. Xu *et al.*also reported up-regulation of liver enriched transcriptional factors in infected HCV tissues \[[@B62]\]. A comprehensive study is needed to address the exact role of these genes. Some genes associated with signal transduction like CACNB3, PCSK5, TMEM100 and VDAC3 were up-regulated in initial fibrosis. Up-regulation of signal transduction related genes in HCC due to HCV and HBV is previously reported \[[@B63],[@B64]\]. This can lead to the hypothesis that cirrhosis due to HCV genotype 3a may lead to HCC in future.

![**Expression of transcription and signal transduction related genes.** Clustering was performed by Cluster 3.0 software.](1479-5876-10-41-10){#F10}

Transport and ion channel transport related genes
-------------------------------------------------

A number of genes encoding cellular and ion transport functions were also recognized (Figure [11](#F11){ref-type="fig"}). AMICA1, HHLA3, KIF17, KIF1A and SLC10A5 showed significant high expression, while, CLPB, K1024, MUC6, SCGN and MT1E expression was down in cirrhotic arrays. Previous studies related to HCV infection and entry has shown that HCV replication needs regulations in cellular trafficking \[[@B65]-[@B67]\]. High expression of SLC10A5, also known as putative bile acid transporter gene, it may indicate dysregulation of liver as well as pancreas in patients infected with HCV. Up-regulation of kinesin family members KIF17 or KIF2B may upset inner segment and synaptic terminal and consequently results in cell death \[[@B68]\].

![**Regulation of transport and ion channel related genes by HCV.**Clustering results for differentially expressed genes between HCV infected patients with initial fibrosis and cirrhosis according to their functions. Genes shown in red are up-regulated, while down-regulated genes are shown in green. Genes shown in black have no expression changes.](1479-5876-10-41-11){#F11}

Others significant genes
------------------------

Irrespective of above mentioned genes; we have also found several genes related to DNA binding proteins, DNA replication, morphogenesis, reproduction and liver function (Figure [12](#F12){ref-type="fig"}). The expression of DNA binding protein and replication genes change from initial fibrosis to cirrhosis. The high expression in early fibrosis may underlie a repair mechanism, whereas, reduced gene expression in cirrhosis stage may indicate that virus has overcome the repair mechanism for its replication resulting in total deterioration of liver cells and structure. It is interesting to note that some genes associated with nervous system and vision pathways were also identified. A lot of uncharacterized genes were also recognized. The link of expression of vision related genes with HCV is not clear.

![**Differential expression of genes associated with DNA binding, DNA replication, liver function, nervous system, vision and uncharacterized.** Clustering results for differentially expressed genes between HCV infected patients with initial fibrosis and cirrhosis according to their functions. Clustering was performed by Cluster 3.0 software. Genes shown in red are up-regulated, while down-regulated genes are shown in green. Genes shown in black have no expression changes. Gene expression profiles were presented on a 2-fold change scale.](1479-5876-10-41-12){#F12}

Real time RT-PCR validation of results
--------------------------------------

Analysis with real time RT-PCR confirmed that the selected genes were significantly differentially expressed in initial fibrosis and cirrhotic samples (Figure [13](#F13){ref-type="fig"}). Although, we observed higher fold induction values with real time RT-PCR, however, the trend was same between both analysis indicating reproducible gene expression patterns. CASPASE9, OAS2 and TGFBR2 genes showed up-regulation, whereas, FAM14B gene expression was down-regulated in early fibrosis. These findings open a new spectrum of genetic markers to differentiate fibrosis from cirrhosis.

![**Validation of microarray data by RT-PCR**. (**A**) Quantification of differential expression of randomly selected genes by real time RT-PCR. (**B**) Expression profile of selected genes from our microarray study.](1479-5876-10-41-13){#F13}

A comprehensive review of literature revealed that very few studies related to HCV expression based studies leading to initial to final stage cirrhosis have been carried out in association to genotype. Walters *et al.*used J6/JFH (genotype 2a) infected Huh-7.5 cells for the expression analysis of host in response to virus at different time points of infection. They observed that TGF-beta signaling genes were up-regulated 72 hrs post infection, it induces ROS activity. Liver injury during chronic HCV infection is immune mediated \[[@B37]\]. Hagist *et al.*compared differentially expressed genes in patients with mild and severe iron depleted HCV genotype 1a liver samples with hereditary hemochromatosis. They found many ISG genes dysregulated in HCV infection and related to RNA processing and carcinogenesis \[[@B69]\]. We also found up-regulation of ISG genes in initial fibrosis stage as host defense system try to limit the viral pathogenesis. A study conducted by Blackham *et al.*in JFH1 infected huh-7 cells by microarray identified genes mainly apoptosis, proliferation, intracellular transport and cellular mechanism \[[@B61]\]. A few studies to explore the role of individual genes of HCV in pathogenesis have been studied in association to genotype. Shah *et al.*compared the expression of oxidative stress related genes in blood samples and found that the expression of COX-2, iNOs and VEGF was high in 3a in comparison to 1a \[[@B70]\]. We found the expression is high in initial fibrosis stage and down regulation at the advance stage of liver cirrhosis.

Conclusion
==========

There are limited studies available dealing with gene expression profiling in cirrhotic and non-cirrhotic (initial fibrosis) patients infected with HCV. In this study, we have observed that HCV infection due to genotype 3a has widespread effects on host gene expression involved in apoptosis, metabolism, transport, transcriptional regulation and immune response. This gives comprehensive information about the pathogenesis caused by HCV genotype 3a leading from initial to end stage liver cirrhosis. Although, HCV genotype 3a showed same pathways activation caused by other genotypes, further studies are required to understand the mechanism by which different genotypes can affect various pathways. Meanwhile, we found that expression of these genes was significantly changed within initial and final stage of fibrosis. A study describing the progression of these genes in mild and severe fibrosis stages (F2 and F3) will be required for future perspectives.
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